	US 12,275,779 B2
	14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
Anthony Marotta, Vancouver (CA)
Assigned to The University of British Columbia, Vancouver (CA)
Filed by The University British Columbia, Vancouver (CA)
Filed on May 3, 2021, as Appl. No. 17/306,913.
Application 17/306,913 is a continuation of application No. 14/798,398, filed on Jul. 13, 2015, granted, now 10,995,136.
Application 14/798,398 is a continuation of application No. 12/745,235, granted, now 9,079,947, issued on Jul. 14, 2015, previously published as PCT/CA2008/002094, filed on Nov. 26, 2008.
Claims priority of provisional application 61/077,123, filed on Jun. 30, 2008.
Claims priority of provisional application 60/990,520, filed on Nov. 27, 2007.
Prior Publication US 2022/0106386 A1, Apr. 7, 2022
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); G01N 33/68 (2006.01); G01N 33/564 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 39/001162 (2018.08); A61K 39/001163 (2018.08); G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); A61K 2039/515 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); G01N 33/564 (2013.01); G01N 2333/47 (2013.01); G01N 2800/102 (2013.01)]

7 Claims

1. An anti-14-3-3 eta antibody, wherein said antibody is produced by hybridoma AUG3-CKNS-7F8, is capable of specifically binding to a human 14-3-3 eta protein in its natural configuration, and exhibits selectivity for said human 14-3-3 eta protein over other human 14-3-3 protein isoforms.